Viewing nowEmpaang Tablet 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 202101834 · Approved 2021.02.24 · Insurance code 657308520
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It can be administered as monotherapy, and in cases where previous diabetes medication experience is lacking or blood sugar control is difficult with monotherapy, it can be used in combination with metformin. Furthermore, this medication can be used as an adjunct to metformin monotherapy or other combinations when adequate blood sugar control is not achieved. It can also be used in conjunction with insulin therapy, particularly when blood sugar control is difficult, to achieve optimal therapeutic effects with various combination therapies. This medication is appropriately used in individuals with type 2 diabetes and cardiovascular diseases who have inadequate blood sugar control. Overall, this medication is used to effectively improve blood sugar control in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older adults No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment with this medicine is not recommended in adults aged 85 years or older because clinical experience is limited (see Precautions for Use, 4. General Precautions)
This medication should not be used in patients allergic to the active ingredient or components of this drug. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This drug is not used in patients with severely reduced renal function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m2, terminal kidney disease, or those undergoing dialysis. This medication contains lactose; hence, patients with genetic conditions like lactose intolerance or galactose intolerance should not take it. In patients with slightly reduced kidney function, this drug should be used with caution, and dosage adjustments or discontinuation may be necessary for those with a glomerular filtration rate of less than 60 mL/min/1.73m2. Some patients with heart failure have limited experience with this drug, so caution is necessary, and it is not recommended for severe heart failure patients. When used with insulin or insulin secretagogues, there may be an increased risk of hypoglycemia, necessitating adjustment of these medications' dosages. This medication may cause adverse reactions such as hypoglycemia, urinary tract infections, genital infections, increased urination, and fluid volume reduction, so careful observation is needed if symptoms occur. Particularly, serious metabolic acidosis known as ketoacidosis may occur, so treatment should be immediately stopped, and a healthcare professional consulted if related symptoms appear. In elderly patients, especially those aged 75 and older, there is a higher risk of fluid volume loss, so careful use is required. This drug may increase the risk of severe infections like urosepsis, pyelonephritis, and perineal necrosis, so immediate hospital visits are necessary if infection symptoms appear. During treatment with this drug, it may affect the testing methods for blood sugar control, so the 1,5-AG test is not recommended for blood sugar monitoring. Women who are pregnant or planning to become pregnant should avoid taking this drug, and breastfeeding mothers should also avoid it. The safety and effectiveness in children under 18 have not been confirmed, so it should not be used in this population. No specific toxic symptoms have been reported in case of overdose, but appropriate treatment may be necessary depending on the clinical situation. This medication should be kept out of the reach of children and should not be transferred to other containers. There is a risk of hypoglycemia while driving or operating machinery, so caution is warranted. There may be interactions with this drug and other medications, so it is essential to inform healthcare providers of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. Additionally, it is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to effectively preserve the drug's efficacy and safety.
Light yellow, convex oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Empagliflozin 10mg
Tablet · Prescription medication
Keeps Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.